Ann Bass, MD
Neurology · San Antonio, TXNPI 1104925171
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,152,594 of the $1,727,538 with a category attached, or 66.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.7%. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,755 payments — averaging $627.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$305K
- EMD Serono, Inc.$293K
- Genentech USA, Inc.$237K
- AstraZeneca$151K
- TG Therapeutics, Inc.$126K
- Amgen$118K
- plus $497K from 54 others
Across 407 payments — averaging $25,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6.3M
- Genentech, Inc.$2M
- Sanofi$862K
- Bristol Myers Squibb$685K
- F. Hoffmann-la Roche AG$568K
- TG Therapeutics, Inc.$90K
- plus $32K from 6 others
What the payments were for
- Consulting fees$321,12919%
- Speaking & faculty fees$1,152,59467%
- Travel & lodging$186,48611%
- Food & beverage$50,4433%
- Education$16,8871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$253,525
- OCREVUS$215,221
- LEMTRADA$137,120
- BRIUMVI$118,302
- ZEPOSIA$113,090
- AUBAGIO$106,011
- SOLIRIS$100,757
- UPLIZNA$98,250
- MAYZENT$67,173
- TYSABRI$37,999
- ZEPBOUND$31,749
- KESIMPTA$30,056
- ULTOMIRIS$29,465
- Ocrevus Zunovo$26,657
- Vumerity$17,928
- DISEASE STATE$13,524
- ACTHAR$12,498
- ARZERRA$7,714
- TECFIDERA$7,229
- Ozanimod$6,365
How this compares
$1,727,538 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 15 | $839,816 |
| Kesimpta PenOfatumumab | 80 | $767,843 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $494,159 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $309,026 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $163,704 |
| AubagioTeriflunomide | 17 | $159,388 |
| Teriflunomide | 57 | $127,901 |
| ZeposiaOzanimod Hydrochloride | 13 | $118,733 |
| VumerityDiroximel Fumarate | 12 | $105,668 |
| Dalfampridine ErDalfampridine | 84 | $88,910 |
| CopaxoneGlatiramer Acetate | 13 | $74,300 |
| BotoxOnabotulinumtoxina | 15 | $24,520 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $24,224 |
| Nurtec OdtRimegepant Sulfate | 13 | $21,331 |
| GraliseGabapentin | 11 | $16,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris | $151,208 | $839,81615 claims |
| CSL BehringPrivigen | $155 | $494,15913 claims |
| Grifols USA, LLCGamunex-C | $268 | $163,70413 claims |
| SanofiAubagio | $304,956 | $159,38817 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $90,895 | $118,73313 claims |
| BiogenVumerity | $85,756 | $105,66812 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $749 | $74,30013 claims |
| AbbVieBotox, Namzaric, Savella | $1,539 | $48,32552 claims |
| PfizerNurtec Odt | $462 | $21,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in San Antonio
- Santiago RestrepoSan Antonio$532K
- Juan Ramirez CastanedaSan Antonio$456K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- Arash SalardiniSan Antonio$125K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.